Skip to main content
. 2020 Aug 27;7:498. doi: 10.3389/fmed.2020.00498

Figure 2.

Figure 2

Anti-dsDNA titres and complement levels. Immunological tests for the CD20-to-belimumab and the CD20-to-CD20 groups. Each figure shows the pre- and post-treatment for the (A) anti-dsDNA titres; (B) complement C3 level and (C) complement C4 level. Points represent median and error bars denote interquartile range. The dotted red lines represent lower limit of the normal values of the tests. BL, Baseline; 6 mo, 6 months.